Back to top

Fate Therapeutics (FATE) Receives a Hold from TD Cowen

TD Cowen analyst Tara Bancroft maintained a Hold rating on Fate Therapeutics (FATE – Research Report) today. The company’s shares closed yesterday ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Fate Therapeutics, Inc. (FATE)